Sei Investments Co. Raises Position in CG Oncology, Inc. $CGON

Sei Investments Co. boosted its position in shares of CG Oncology, Inc. (NASDAQ:CGON) by 111.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,089 shares of the company’s stock after buying an additional 9,542 shares during the period. Sei Investments Co.’s holdings in CG Oncology were worth $1,225,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. NFSG Corp purchased a new stake in shares of CG Oncology during the first quarter worth approximately $34,000. Comerica Bank lifted its holdings in CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares in the last quarter. LPL Financial LLC lifted its holdings in CG Oncology by 9.8% in the 4th quarter. LPL Financial LLC now owns 6,201 shares of the company’s stock valued at $257,000 after purchasing an additional 551 shares in the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new stake in CG Oncology during the 4th quarter worth $27,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in CG Oncology by 33.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock worth $163,000 after purchasing an additional 972 shares during the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Trading Up 0.6%

NASDAQ CGON opened at $77.03 on Wednesday. The stock has a fifty day simple moving average of $67.90 and a 200-day simple moving average of $64.31. The stock has a market cap of $6.83 billion, a PE ratio of -28.64 and a beta of 0.23. CG Oncology, Inc. has a twelve month low of $24.10 and a twelve month high of $77.49.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.24). The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $0.36 million. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 26.58%. Research analysts predict that CG Oncology, Inc. will post -3.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Piper Sandler increased their target price on shares of CG Oncology from $82.00 to $85.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Wall Street Zen downgraded shares of CG Oncology from a “sell” rating to a “strong sell” rating in a report on Saturday. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of CG Oncology in a report on Wednesday, July 29th. Royal Bank Of Canada dropped their price target on CG Oncology from $81.00 to $79.00 and set an “outperform” rating for the company in a research report on Friday, August 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a research report on Friday, July 17th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $83.18.

Insider Transactions at CG Oncology

In other CG Oncology news, Director James Mulay sold 24,165 shares of the company’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $75.16, for a total transaction of $1,816,241.40. Following the transaction, the director directly owned 24,165 shares in the company, valued at $1,816,241.40. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Leonard E. Post sold 5,000 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total value of $350,000.00. Following the transaction, the director owned 5,000 shares of the company’s stock, valued at approximately $350,000. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 37,129 shares of company stock worth $2,663,817. 4.80% of the stock is currently owned by insiders.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.